PLUS THERAPEUTICS INC PSTV 深 滬
等待開盤 08-07 09:30:00 美东时间
0.7598
+0.102
+15.47%
華盛通- 最 高0.804
- 今 開0.70
- 成交量 1911.59万股
- 最 低 0.6891
- 昨 收 0.658
- 總市值 3874.87万
- 52周最高 2.3099
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 0.1634
- 委 比 46.06%
- 總股本 5099.85万
- 歷史最高 343.35
- 量 比 0.72
- 振 幅 17.46%
- 歷史最低 0.1634
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Soligenix (NASDAQ:SNGX) shares rose 192.0% to $3.65 during Thursday's ...
08-01 01:08
Plus Therapeutics Launches CNSide Diagnostic In Texas With Initial Focus On NCI-Designated Cancer Centers
CNSide available for the state of Texas in August 2025Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systemsCompany will expand testing services and broaden regional availability
07-31 19:36
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
Houston-based Plus Therapeutics subsidiary CNSide Diagnostics will launch its CSF assay platform for detecting cancer metastases in the central nervous system in Texas in August 2025. The initial commercial focus will be on NCI-Designated Cancer Centers and large healthcare systems. The CNSide assay offers high sensitivity (92%) and specificity (95%), surpassing traditional CSF cytology methods. It has been used in over 11,000 tests since 2020 an...
07-31 11:30
Plus Therapeutics announces $1.6 million advance payment from CPRIT
Plus Therapeutics (NASDAQ:PSTV) Wednesday said that it has received notice of an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas. The payment is part of the ...
07-23 19:41
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
Plus Therapeutics will present ReSPECT-LM trial results and host an educational symposium on leptomeningeal metastases (LM) at the 2025 SNO/ASCO CNS Metastases Conference in Baltimore. The presentation will focus on the safety and efficacy of REYOBIQ for LM treatment, with discussions on its potential to improve patient outcomes. The symposium, featuring leading neuro-oncologists, will explore advancements in LM management. CNSide Diagnostics wil...
07-15 11:30
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present two studies at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, in Baltimore, MD. The studies focus on the clinical utility of the CNSide CSF Assay Platform for detecting and quantifying tumor cells in cerebrospinal fluid (CSF) in patients with leptomeningeal disease. Priya Kumthekar, M.D., will ...
07-10 11:30
PLUS Therapeutics shares are trading higher after the company announced the treatment of initial patients for its ReSPECT-LM dose optimization trial of REYOBIQ.
PLUS Therapeutics shares are trading higher after the company announced the tre...
07-08 20:43
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Houston-based Plus Therapeutics has initiated the ReSPECT-LM dose optimization trial for REYOBIQ, targeting leptomeningeal metastases (LM). Building on Phase 1 results, the trial aims to determine optimal dosing regimens for maximum safety and efficacy, supported by a $17.6M CPRIT grant. Previously, the single-dose trial demonstrated a 76% clinical benefit rate and no dose-limiting toxicities in early cohorts. The ReSPECT-LM trial will enroll up ...
06-30 11:30
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
Plus Therapeutics, Inc. will commercially launch its CNSide CSF Assay Platform for diagnosing CNS metastases in the U.S. in late 2025, targeting a $6+ billion underserved market. The platform, which offers superior sensitivity (92%) and specificity (95%) compared to traditional methods, has been used in over 11,000 tests since 2020. The company plans rapid expansion across the U.S. and has secured payor agreements. Management will host a conferen...
06-26 11:30
